{"id":"W2278057905","doi":"10.1200/jco.2004.22.90140.7022","title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Erlotinib Hydrochloride; Regimen; Chemotherapy; Pemetrexed; Oncology; Carboplatin; Chemotherapy regimen; Placebo; Randomized controlled trial; Gastroenterology; Epidermal growth factor receptor; Cancer; Cisplatin; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002397177,0.002698548,0.003748155,0.0006453644,0.0007747953,0.001324427,0.001336692,0.00336333,0.01169788],"category_scores_gemma":[0.002907353,0.0009195485,0.001941766,0.0004780668,0.001775375,0.001411389,0.0005744772,0.003863545,0.002269789],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008337751,"about_ca_system_score_gemma":0.001409402,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001083496,"about_ca_topic_score_gemma":0.002480722,"domain_scores_codex":[0.9988756,0.000587415,0.00007845955,0.0002281763,0.00006810582,0.0001622928],"domain_scores_gemma":[0.9985778,0.0004096445,0.000347177,0.0001347095,0.00009831317,0.0004323994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9929997,0.003053048,0.0001315394,0.0002090815,0.0002339303,0.00001732827,0.00001564733,0.00007105654,0.0004807369,0.00004228785,0.000334082,0.002411552],"study_design_scores_gemma":[0.9821162,0.01704243,0.0003148747,0.00001120857,0.00009741163,0.000008920085,0.000005502417,0.00009971673,0.00007400368,0.00004595712,0.0001796718,0.000004126165],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9606349,0.006231887,0.0009638801,0.001978307,0.002884747,0.01845466,0.003058183,0.000307132,0.00548631],"genre_scores_gemma":[0.9704323,0.002410474,0.001724409,0.002159652,0.001275173,0.013415,0.002330768,0.00003154657,0.006220647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9989165,"threshold_uncertainty_score":0.03913331,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0520902160985434,"score_gpt":0.4512543726723138,"score_spread":0.3991641565737704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}